434 related articles for article (PubMed ID: 21300721)
1. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
2. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
4. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
5. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500
[TBL] [Abstract][Full Text] [Related]
7. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
Crumb WJ; Vicente J; Johannesen L; Strauss DG
J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
[TBL] [Abstract][Full Text] [Related]
9. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
[TBL] [Abstract][Full Text] [Related]
10. Computational approaches to understand the adverse drug effect on potassium, sodium and calcium channels for predicting TdP cardiac arrhythmias.
Sharifi M
J Mol Graph Model; 2017 Sep; 76():152-160. PubMed ID: 28756335
[TBL] [Abstract][Full Text] [Related]
11. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Lu HR; Hermans AN; Gallacher DJ
Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
[TBL] [Abstract][Full Text] [Related]
12. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
13. Effect of azelastine on cardiac repolarization of guinea-pig cardiomyocytes, hERG K⁺ channel, and human L-type and T-type Ca²⁺ channel.
Park MH; Lee SH; Chu DH; Won KH; Choi BH; Choe H; Jo SH
J Pharmacol Sci; 2013 Sep; 123(1):67-77. PubMed ID: 24005046
[TBL] [Abstract][Full Text] [Related]
14. Effects of common antitussive drugs on the hERG potassium channel current.
Deisemann H; Ahrens N; Schlobohm I; Kirchhoff C; Netzer R; Möller C
J Cardiovasc Pharmacol; 2008 Dec; 52(6):494-9. PubMed ID: 19034038
[TBL] [Abstract][Full Text] [Related]
15. Early prediction of proarrhythmic cardiotoxicity in the drug development process.
Anyukhovsky EP
Cardiovasc Res; 2011 Jul; 91(1):7-8. PubMed ID: 21555404
[No Abstract] [Full Text] [Related]
16. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
17. Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
Kimura K; Tabo M; Itoh M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
J Toxicol Sci; 2007 Aug; 32(3):217-30. PubMed ID: 17785939
[TBL] [Abstract][Full Text] [Related]
18. Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks.
Sharifi M; Buzatu D; Harris S; Wilkes J
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):497. PubMed ID: 29297274
[TBL] [Abstract][Full Text] [Related]
19. Use of high throughput ion channel profiling and statistical modeling to predict off-target arrhythmia risk - One pharma's experience and perspective.
Watt ED; Lee T; Feng SL; Kilfoil P; Ackley D; Keefer C; Wisialowski T; Jenkinson S
J Pharmacol Toxicol Methods; 2022; 118():107213. PubMed ID: 36084863
[TBL] [Abstract][Full Text] [Related]
20. Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels.
Kuryshev YA; Bruening-Wright A; Brown AM; Kirsch GE
J Cardiovasc Pharmacol; 2010 Oct; 56(4):420-30. PubMed ID: 20930594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]